Observation of clinical effect of leukotriene receptor antagonist in the treatment of patients with PF-COPD

Objective To evaluate the therapeutic effect of leukotriene receptor antagonist(Montelukast Sodium Chewable Tablets,Shun Erning) in the treatment of patients with PF-COPD.Methods 40 patients with PF-COPD were all given conventional treatment,including oxygen therapy,reduce phlegm,pulmonary function exercises and salbutamol inhalation,and then they were randomly and evenly divided into two groups.The treatment group was additionally treated with 1 tablet of Shun Erning everyday for 3 months.The changes of clinical symptoms,blood gas analysis,pulmonary function and HRCT image were observed before and 3 months after the treatment.Results After the treatment,the improvement of dyspnea scores and exercise tolerance was more pronounced in the treatment group than in the control group with significant difference(P0.05).The levels of PaO2,VC%,FEV1% pred and DLCO% of the treatment group were significantly improved 3 months after the treatment(P0.05),but there was no significant difference in the control group before and 3 months after the treatment(P0.05).Conclusion Leukotriene receptor antagonist is and effective and feasible method in the treatment of patients with PF-COPD.